Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4A Clinical benefit achieved from subsequent lines of endocrine therapy in patients with de novo resistance to 1st line endocrine therapy

From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

Lines of Endocrine therapy 2 nd line 3 rd line 4 th line
N 17 9 4
N of CB (%) 5 (29.4) 2 (22.2) 0
Median DOR with CB (months) 12.0 (7–29) 14.0+(11–17) Not applicable
N still receiving treatment 0 1 0
  1. + = including patients who are still on treatment, therefore would have additional duration of response on a later analysis; CB = Clinical Benefit; DOR = Duration of Response